<DOC>
	<DOCNO>NCT00615550</DOCNO>
	<brief_summary>The purpose research study evaluate usefulness progesterone vaginal gel decrease preterm birth rate population pregnant woman short cervical length high risk preterm birth .</brief_summary>
	<brief_title>PREGNANT Short Cervix Trial</brief_title>
	<detailed_description>A Short uterine cervical length mid-trimester powerful predictor preterm birth .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>1 . The subject short cervical length transvaginal ultrasound ( TVU ) define 1020mm . In case `` dynamic cervix '' , short observed/documented cervical length TVU use cervical length inclusion purpose . 2 . Singleton gestation . 3 . The pregnancy estimate gestational age 19 0/7 week 23 6/7 week . 4 . Maternal age 15 ( local age majority/emancipation ) 45 year age time screen . An alternative age range accept accord standard applicable regulation study center . 5 . The subject speak either English common local language . 6 . The subject voluntarily sign Informed Consent Form associate form content explain , question answer satisfaction understanding . 7 . In opinion investigator , subject able understand study able give inform consent , well participate adhere study procedure . 1 . The subject cervical length &lt; 10 &gt; 20mm . 2 . The subject multifetal gestation . 3 . The subject schedule cervical cerclage prior randomization . According ACOG Practice Bulletin Number 48 ( November 2003 ) , cerclage consider subject history 3 unexplained midtrimester pregnancy loss preterm deliveries.228,229 4 . Subjects diagnose acute cervical insufficiency bulge membrane pass external o . 5 . The subject previous history adverse reaction progesterone component present ProchieveÂ® 8 % vaginal gel . 6 . The subject treat progestogen within previous 4 week . 7 . The subject currently treat seizure disorder , unstable psychiatric disorder , take antihypertensive therapy chronic hypertension time enrollment , history congestive heart failure chronic renal failure , uncontrolled diabetes mellitus ( know endorgan dysfunction secondary vascular disease ) . 8 . The subject active thrombophlebitis thromboembolic disorder , history hormoneassociated thrombophlebitis thromboembolic disorder . 9 . The subject active liver dysfunction disease . 10 . The subject know suspected malignancy breast genital organ . 11 . The subject currently participate another interventional study participate interventional drug study within one month prior screen study . 12 . The subject 's current pregnancy complicate major fetal anomaly know chromosomal abnormality . 13 . The subject uterine anatomic malformation ( bicornuate uterus , septate uterus ) 14 . The subject , judgment investigator , unable unwilling comply studyrelated assessment procedure . 15 . The subject currently preterm rupture membrane , vaginal bleeding , know suspected amnionitis , sign symptom preterm labor time enrollment . 16 . The subject HIV positive CD4 count &lt; 350 cells/mm3 receive one ( 1 ) medication prevent transfer AIDS fetus . 17 . Complete placenta previa .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Preterm</keyword>
	<keyword>Cervix</keyword>
</DOC>